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1. Introduction 
Acute myeloid leukaemia (AML) is a clonal, malignant disease of hematopoietic tissue 
characterized by accumulation of abnormal cells, mainly leukaemic blasts in bone marrow 
and impaired production of normal hematopoietic cells. Leukaemia was discovered in 1845, 
roughly at the same time by two doctors, Rudolph Virchow, a young Berlin pathologist and 
a Scottish pathologist, John Hughes Bennett. The term leukaemia was first used by Rudolph 
Virchow to describe the blood appearance of his female patient after she died. She was a 50-
year-old cook, admitted to hospital, complaining of fatigue, frequent nosebleeds and 
swelling of the legs and abdomen. They were the first who begun to understand what 
exactly goes wrong in this unusual disease. 
The aim of this chapter is to present a step by step approach in diagnosing acute myeloid 
leukaemia and also to identify potential diagnostic pitfalls. 
2. Signs and symptoms 
The clinical course of AML, treated or untreated, is complex, so care for these patients 
requires the experience of a specialist physician. Signs and symptoms usually seen in AML 
are associated with complications, meaning signs and symptoms associated with anaemia, 
thrombocytopenia, and leukopenia and also signs of organ involvement. Without being 
specific, they reflect the anaemia development, but there is no direct proportionality 
between the severity of anaemia and the manifestation of these signs and symptoms: 
fatigue, asthenia, weakness, pallor, dizziness, irritability, dyspnea, tachycardia, palpitations, 
and general lack of wellness. Petechial, nosebleeds, gum bleeding, conjunctivas 
haemorrhage, prolonged bleeding from mild skin lesions, these all reflect the 
thrombocytopenia and are common early manifestations of the disease. Bleeding of the 
gastrointestinal tract, genital-urinary, lung or central nervous system (CNS) may occur 
infrequently. 
According to Hu et al. the frequencies of the most important presenting features in AML are 
presented below in Table 1 (Hu et al., 2011). 
Blood transfusions may be necessary but can – in the case of hyperleukocyosis - also lead to 
a rapid increase in blood viscosity and compromise blood flow. In addition, coagulation 
abnormalities, including disseminated intravascular coagulation, increase the risk of local 
haemorrhage. The use of platelet transfusion is recommended, especially since the number 
of platelets may be overestimated due to the presence of fragments of blasts that are 
wrongly considered by the automated haematology analyzers. Acute promyelocytic 
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leukaemia is most commonly associated with intravascular coagulation and bleeding 
(Tallman & Kwaan, 2004). Platelets interact with normal peripheral blood (PB) cells via 
soluble mediators of adhesion molecules and these, once released, may affect hematopoietic 
stem and progenitor cells. Recently the interactions between platelets and AML cells has 
been characterized in detail (Foss & Bruserud, 2008): blasts and platelets can affect each 
other’s functions, drugs used to treat AML can alter some platelet functions, systemic levels 
of cytokines are increased during chemotherapy, including cytokines known to affect 
platelet activation and blasts, platelet secretion of growth factors is clearly detected in 
peripheral blood of persons with stem cell autografts. 
 
Acute Myeloid Leukaemia 
Initial symptom 
Younger 
Group (age < 60) 
 % 
Elderly 
Group (age ≥ 60) 
% 
Hypodynamia 57.8 68.3 
Pale face 60.3 55.5 
Fever 40.5 33.5 
Dizziness 14.7 10.4 
Hemorrhagic dermatologic mucosa 15.5 14.0 
WBC infiltration 6.9 12.2 
Myalgias 4.3 3.0 
White cell count (109/L)   
 < 4 24.1 40.2 
 4 - 10 16.4 9.8 
 > 10 59.5 50.0 
Haemoglobin (g/L)2   
 Abnormal 93.1 95.7 
 Normal 6.9 4.3 
Platelets (109/L)   
 ≤10 29.3 21.3 
 >10 70.7 78.7 
Bone marrow cellularity   
 Severely hypercellular 53.4 30.5 
 Moderately hypercellular 21.6 34.8 
 Normocellular 13.8 20.7 
 Hypocellular 11.2 14.0 
Table 1. The frequencies of the most important presenting features in AML, according to Hu 
et al. 
Infections remain a major cause of morbidity and mortality associated with therapy in 
both adults and children with AML. Pustules or other skin infections and various skin 
lesions are the most common minor infections encountered. More serious infections like 
sinusitis, pneumonia, pyelonephritis and meningitis occur rarely in the beginning. After 
starting chemotherapy, with aggravation of neutropenia and monocytopenia, serious 
infections occur more frequently with various bacterial, fungal or viral agents. Progressive 
decline in immune function makes aged patients with AML theoretically more susceptible 
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to nosocomial infection than younger ones. However, a study in this regard indicated that 
there is no significant difference in the overall incidence of infections, such as febrile 
episodes, the pattern of nosocomial infection sites, the average duration of antimicrobial 
therapy and overall survival (Fanci et al., 2008). Gram-negative bacteria were more 
common in patients with severe sepsis (Hämäläinen et al., 2008). A case was reported in 
the literature of AML with marked hyponatremia and impaired consciousness probably 
due to treatment with linezolid, but sodium supplementation restored the natremia. 
Viridans streptococci in children with AML are a major cause of infections and 
pneumonia in cases with neutropenia. Viridans streptococci sepsis developed at different 
times after chemotherapy was initiated and patients were febrile for a median of 15 days. 
33% of the 172 children with AML included in this study had hypotension, 28% had acute 
respiratory distress syndrome and 17% had fungal infections (Okamoto et al., 2003). 
Neutropenic enterocolitis and acute appendicitis are also complications that occur in 
children with severe or prolonged neutropenia, and may endanger their lives (Alioglu et 
al., 2007). Hepatosplenic fungal infections are important infectious complications in adults 
with AML being diagnosed with computerized tomography and high levels of alkaline 
phosphatase. Mortality related to these infections is low if treatment is appropriate 
(Masood & Sallah, 2005). 
Fever is present at diagnosis in approximately 40-50% of the patients. Anorexia and weight 
reduction are also common, percentages of 25% being reported (Burns et al., 1981). 
Splenomegaly and hepatomegaly are seen in approximately one third of patients, especially 
in those with a monocytic or monoblastic morphologic subtype. Adenopathy is rare, the 
exception being the monocytic variant of AML where a frequency of more than 30% can be 
found (Burns et al., 1981; Hu et al., 2011). 
2.1 Specific organ involvement 
Blast cells are circulating and infiltrating various tissues. Occasionally, a biopsy or autopsy 
reveals infiltration with leukaemic cells at different levels. They cause disruption to the 
affected structures. Extramedullary involvement is more frequent in monocytic and 
myelomonocytic leukaemia. Recently it was demonstrated that haematopoietic progenitors 
and leukaemic cells are retained in the bone marrow (BM) microenvironment through 
chemokine receptors, such as CXCR4. A prospective study evaluated by flow cytometry the 
prognostic involvement of CXCR4 in AML. The study showed that low expression of 
CXCR4 on leukaemic cells is correlated with a better prognosis than high expression (Spoo 
et al., 2007). Different sites may be involved (Liesveld & Lichtman, 2006): 
Skin involvement. Skin injury prior to BM and blood involvement is rare and can be of three 
types: nonspecific lesions (maculae, papules, vesicles, pyoderma gangrenosum, vasculitis, 
neutrophilic dermatitis, erythema multiform or nodosa), skin leukaemia and granulocytic 
sarcomas (myeloid sarcomas), being the result of skin infiltration by blastic cells. The most 
common sites of infiltration are the scalp, trunk and extremities. 
Sensory organ involvement. Sensory organ involvement is very rare, however, infiltration of 
retina, choroids, iris and optic nerve may occur. Otitis external and internal bleeding, 
infiltration of the mastoid with VII nerve damage may be other signs of disease 
presentation. 
Gastrointestinal tract involvement. May be affected at any level, but functional disorders are 
rare. Involvement of the oral cavity, colon and anal canal most often lead to symptoms. 
Involvement of the oral cavity often means the patient goes to the dentist. Infiltration of 
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gums, periodontal abscess can cause prolonged bleeding following extractions. Enterocolitis 
may be a way of disease presentation or can occur during treatment. Fever, abdominal pain, 
bloody diarrhoea or ileus may be present and sometimes mimic appendicitis. Isolated 
gastrointestinal tract involvement is rare. Proctitis usually occurs in the monocytic variant of 
leukaemia and is a difficult problem to solve during the period with severe 
granulocytopenia. 
Respiratory tract involvement. Infiltrates may lead to laryngeal obstruction, functional 
disorders, severe symptoms and radiological changes in the case of parenchymal, alveolar 
or pleural infiltrates. 
Heart involvement. Cardiac involvement is common, but rarely causes symptoms. 
Pericardial infiltrates, ventricular transmural endocarditis can occasionally cause severe 
cardiac arrhythmias or even death. Infiltrations of the excitoconductor system and 
myocardial infarction were also cited. 
Urogenital tract involvement. The kidneys are infiltrated with leukaemic cells in a large 
number of cases, but functional disorders are rare. Bleeding into the collector is common. 
Cases have been cited with vulvar, prostatic and testicular penetration. 
Osteoarticular system involvement. Its involvement is accompanied by various degrees of 
bone and joint pain. Bone necrosis may also occur. Pseudo-gout arthritis (calcium 
pyrophosphate dehydrate) or gout arthritis (uric acid) is sometimes responsible for 
synovitis. 
Central nervous system involvement (CNS). CNS involvement is rare, although meningeal 
infiltration is seen in the monocytic type of AML. An association between CNS involvement 
and diabetes insipidus has been reported in AML with monosomy 7 and inv16 (Castagnola 
et al., 1995). 
Granulocytic sarcomas. Also known as sarcomas or chloromas, myeloid sarcomas are 
tumours composed of myeloblasts, monoblasts or megakaryocytes. These tumours can 
occur as extramedullary masses without evidence of leukaemia in BM or peripheral blood 
(nonleukaemic myeloid sarcomas) or in combination with leukaemia. When they appear as 
isolated lesions they are usually chloromas and considered extranodal lymphoma, because 
of the biopsy appearance similar to lymphoid cells. When myeloid sarcoma is the first 
manifestation of AML, the involvement of BM and blood appears after a few months. 
Theoretically myeloid sarcomas can have any location: skin, orbit, paranasal sinuses, bone, 
chest wall, breast, gastrointestinal tract, respiratory, genital-urinary, central nervous system, 
peripheral nervous system or lymph node (Hernández et al., 2002; Liesveld & Lichtman, 
2006; Paţiu et al., 2008). Abnormalities involving chromosome 8 are the most common 
cytogenetic abnormalities in nonleukaemic sarcomas (Tsimberidou et al., 2003). Initially, 
these tumours were termed chloromas because of the green colour due to the presence of 
myeloperoxidase in myeloid leukaemic cells. Patients with AML with t(8;21) have a 
propensity to develop extramedullary leukaemia with poor outcomes after treatment. 
2.2 Neonatal and childhood AML 
A study conducted between May 1988 and June 2000 that included 698 children with AML 
tried to find the relationship between the age of onset of the disease, clinical characteristics 
and evolution. AML onset was observed at a very young age and is accompanied by 
intermediate risk cytogenetics (high incidence of 11q23 translocations). French-American-
British (FAB) distribution is also based on age: types M5 and M7 are more common at 
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younger ages and types M0, M2, M3 more common in older children. In terms of clinical 
diagnosis, CNS involvement and digestive tract involvement is more common in very 
young children. Very young children develop severe diarrhoea, nausea and vomiting after 
chemotherapy (Webb et al., 2001). A recent study shows the impact of the undifferentiated 
form of AML-M0 on disease progression in children with AML with and without Down 
syndrome (DS), analyzing two clinical trials (Children's Cancer Group Clinical Trials AML). 
The main issues pursued were morphology and cytogenetics. Children with AML-M0 
without DS had a lower number of leukocytes than patients with non-M0 AML and a higher 
incidence of del5, non constitutive trisomy 21 and hypoploidy. The analysis of AML in 
children without DS showed no differences between cases and non-M0 M0. Also there was 
no difference in evolution between children with DS and M0 and those with DS and non-M0 
AML (Barbaric et al., 2007). 
Four AML related syndromes are described in newborns: 
 Transient myeloproliferative disease that may be present at birth or immediately after 
in about 10% of children with DS. The syndrome is followed shortly by acute 
leukaemia, usually myeloid (less common lymphoblastic). 
 Transient leukaemia. 25% of children with DS and transient leukaemia develop AML - 
M7 in the first 4 years of life. 
 Congenital Leukaemia.  
 Neonatal leukaemia. Children who develop leukaemia during the first weeks of life are 
often pale, with insufficient increase in weight, diarrhoea and lethargy. The presence of 
cytogenetic abnormalities involving chromosome 11 has an extremely unfavourable 
prognosis.  
The last two syndromes can occur in children without DS, but 10 times less frequently than 
in those with DS. Leukocytosis, bone marrow and blood infiltration with blasts, hepato-
splenomegaly, thrombocytopenia, anaemia, purpura and skin infiltrates are common 
manifestations. Unfortunately, these children do not survive more than a few weeks or 
months. The disease can be highlighted during the prenatal period because cytogenetic 
abnormalities appear and mark the leukaemic clone. Monocytic differentiation of leukaemia 
and t(4;11) are common features. A case was even reported of transplacental transmission of 
acute monocytic leukaemia (Liesveld & Lichtman, 2006). 
2.3 Elderly AML 
AML in the elderly is a biologically distinct clinical entity. AML is generally a disease of old 
age, because the diagnosis is usually made in the decade of 60-70 years. The unfavourable 
course of the disease is due to biological characteristics at this age and various associated co-
morbidities. In the United States the elderly population is the fastest growing segment, the 
average age at diagnosis of AML being 67 years (Melchert, 2006). Some data indicate that 
the disease develops from haematopoietic precursors that are in an early stage of maturation 
and may thus involve more than one haematopoietic line. This could explain the clinical and 
biological behaviour of the disease and prolonged neutropenia after chemotherapy. In 
addition, a large number of blasts express drug resistance glycoprotein - MDR1 and the 
incidence of unfavourable cytogenetics is high (7-, 5-). These factors, rather than age itself, 
are responsible for the unfavourable evolution of the disease. Compared to younger ages 
AML, AML in the elderly often derives from a previous haematological disease or after 
treatment for another malignancy. The morphological signs of dysplasia are frequently 
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observed (Ferrara & Pinto, 2007; Hiddemann et al., 1999). Many of these patients cannot 
cope with intense chemotherapy and its complications. The acute toxicity of chemotherapy 
is greater in patients with chronic heart, lung, liver or kidney disease. For example, age-
related reduction of left ventricular ejection fraction limits the use of anthracyclines or 
mitoxantrone. Cardiotoxicity can occur at any time during mitoxantrone therapy and the 
risk increases with cumulative dose. Congestive heart failure, potentially fatal, may occur 
either during therapy with mitoxantrone or months to years after termination of therapy. 
The risk of symptomatic congestive heart failure was estimated to be 2.6% for patients 
receiving up to a cumulative dose of 140 mg/m2. Elderly patients also have reduced 
regenerative capacity of BM, even if the cytoreduction treatment was successful. Their 
inability to tolerate long periods of pancytopenia, malnutrition and toxicity of 
aminoglycosides or amphotericin are major barriers to successful treatment 
(Rathnasabapathy & Lancet, 2003). 
3. Laboratory investigations 
3.1 Complete Blood Count (CBC) 
BM infiltration by leukaemic cells is almost invariably accompanied by anaemia and 
thrombocytopenia, absolute neutrophil count being low or normal depending on the total 
number of leukocytes. 
Although CBC is a routine investigation, it has not lost its relevance in the diagnosis of 
haematological diseases and hence in AML. CBC helps to highlight the three major 
complications in AML: infections (due to neutropenia), anaemia (low value of haemoglobin, 
low red blood cells count) and bleeding (due to thrombocytopenia). 
The first clue for the diagnosis of AML is an anomalous result of the total number of 
leukocytes. Between 5-20% of patients may present with a very large number of cells (> 100 
x 109/L). Although leukocytosis is a frequent feature, AML may also present with a normal 
leukocyte count and only a low number of platelets and erythrocytes, or even leukopenia 
(aleukaemic forms of AML).  
The blast cells may be counted as lymphocytes or monocytes by the automated haematology 
analyzers and frequently not counted at all. Another important issue is that the analyzers 
cannot differentiate between myeloblasts and lymphoblasts. Eosinophilia and basophilia 
may be present in some subtypes of AML. 
CBC is used after the diagnosis to monitor disease progression and also has prognostic 
impact. It is known that the increased number of leukocytes (> 30000/microL or number of 
blasts > 15000/microL) and a very low number of platelets (< 30000/microL) are factors of 
poor prognosis in AML. 
3.1.1 Hyperleukocytosis and leukostasis 
Leukaemic cells are considerably less deformable than mature myeloid cells. With the 
increasing number of blasts in PB, leukocytosis (total leukocyte count > 10000/microL) or 
hyperleukocytosis (total leukocyte count > 100000/microL) appears and microcirculation is 
threatened by the formation of caps from these rigid cells. Local hypoxemia may be 
exacerbated by increased metabolic activity of blasts and by the production of various 
cytokines. These events lead to impaired endothelial integrity and haemorrhage occurring in 
the existing fund of hypoxia. 5% of patients with AML develop signs and symptoms due 
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hyperleukocytosis. Circulation of the central nervous system and of the lungs is the most 
susceptible to the effect of leukostasis. Cerebral haemorrhage due to vascular occlusion is 
the most aggressive manifestation.  
3.1.2 Hypoplastic leukaemia 
10% of AML patients have pancytopenia, often with no blasts in peripheral blood, without 
hepato-splenomegaly. Three quarters of these patients are men aged over 50 years. A BM 
biopsy shows a hypocellular aspect, but blasts present in a ratio of 15-90%. Hypoplastic 
leukaemia must be distinguished from aplastic anaemia and hypoplastic myelodysplastic 
syndrome. Diagnosis is made on the presence of ≥ 20% blasts in the hypocellular marrow. A 
history of toxic exposure (chemicals, alcohol or chemotherapy for another malignancy) was 
demonstrated in approximately 20% of these cases (Gladson & Naeim, 1986). 
3.1.3 Oligoblastic leukaemia 
In 10% of cases, usually in patients aged over 50 years, AML manifests with anaemia and 
thrombocytopenia, white blood cell count is low, normal or increased. The proportion of 
blasts present in peripheral blood varies from 0-19% and between 3-20% in the BM. These 
cases are classified either as oligoblastic myeloid leukaemia or myelodysplastic syndrome, 
especially refractory anaemia with blasts excess. The disease has high morbidity and 
mortality through infections and bleedings. 
3.1.4 Red blood cell count 
Anaemia is almost always present in AML, because of inadequate production of RBC in the 
BM and shortened lifespan. Anisocytosis and poikilocytosis are variously reflected in 
erythrocyte indices and Price Jones curve. A vicious chain develops when bleedings occur, 
but the BM is not able to produce new erythrocytes. The reticulocyte number is usually low. 
3.1.5 Platelet count 
The platelet count is usually low, with different degrees of thrombocytopenia. In rare cases 
the platelet number can be normal. The mechanisms of thrombocytopenia are inadequate 
production of platelets in the BM and shortened lifespan. The platelets are usually big in 
size as shown by increased medium platelet volume on CBC.  
3.2 Blood smear 
Diagnosis and classification of AML is becoming increasingly complex. Current 
classifications refer to morphological features, immunophenotype and genetics in order to 
classify the different subtypes of leukaemia. Still, a competent and rigorous microscopic 
examination remains essential for diagnosis of AML. 
Presumptive diagnosis of AML can be made by examining the peripheral smear, where 
leukaemic blasts are circulating in peripheral blood, but definitive diagnosis is made by 
examination of the aspirate or biopsy of BM. Classic May-Grunwald-Giemsa staining of 
peripheral blood and BM are used. Currently the diagnosis of AML is based on the evidence 
of 20% blasts in BM. In some cases, if the condition of patient does not allow the puncture of 
BM or biopsy and if there is evidence of 20% blasts in peripheral blood, the diagnosis can be 
made. On the other hand, we must not forget that some patients do not have blasts in their 
blood, so we could erroneously conclude it is not leukaemia. In such cases, if there is a 
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suspicion of haematologic malignancy (anaemia, thrombocytopenia) the examination of BM 
is obligatory. 
In the past 30 years the classification of AML has been done after the FAB system (French-
American-British Cooperative Group classifications of AML), based on morphological and 
cytochemical criteria and includes eight types of AML: M0-M7.  
 M0 (AML with minimal differentiation) 
 M1 (AML without maturation) 
 M2 (AML with maturation granulocyte) 
 M3 (promyelocytic) or acute promyelocytic leukaemia  
 M4 (acute myelomonocytic leukaemia) 
 M4Eo (with BM eosinophilia) 
 M5 monoblastic acute leukaemia (M5a) or acute monocytic leukaemia (M5b) 
 M6 (acute erythroid leukaemia) that includes erythroleukemia (M6a) and very rarely 
pure erythroblast leukaemia (M6b) 
 M7 (acute megakaryoblastic leukaemia) 
Blast morphology is considered of three types based on the cytoplasmic content in 
azurophilic granules: type I myeloblasts with no cytoplasmic granules, type II myeloblasts 
with less than 20 azurophilic granules and type III myeloblasts with more than 20 
azurophilic granules in their cytoplasm. Type II and III may also contain Auer rods (Naeim 
& Rao 2008). The percentage of Auer rods recognized by Wright-Giemsa (WG) staining was 
20.8%, but three times higher by peroxidase staining techniques (Jain et al., 1987). In 
peripheral blood a variable number of blasts are present and not related with the number of 
myeloblasts in the BM. Sometimes the BM is highly infiltrated, even if we have few blasts in 
the blood. Usually, blast morphology in the peripheral blood is in concordance with the BM, 
although sometimes differences may occur (differential diagnosis with acute lymphoblastic 
leukaemia, some lymphomas). So, both attentive examination of blood smear and BM are 
needed. 
Red blood cells morphology is variously affected, with large and small erythrocytes 
(anisocytosis) and different shapes especially if the leukaemia developed from a 
myelodysplastic syndrome (ovalocytes, tear drop erythrocytes). Erythroblasts and stippled 
erythrocytes may also be present.  
Thrombocytes may be giant or with granulation abnormalities (usually hypogranulated).  
Different dysplastic changes may be present if AML has undergone transformation from 
myelodysplastic syndrome: hyper/hypo granulation or hyper/hypo segmentation of 
granulocytes. 
3.3 Bone marrow examination 
Currently, the diagnosis of acute myeloid leukaemia is based on the presence of a minimum 
of 20% blasts in the BM.  
By the term blasts we understand myeloblasts, promonoblasts, monoblasts, megakarioblasts 
or promyelocytes. According to the World Health Organization (WHO) 2008, an exception 
from the 20% rule is possible, if there is evidence of AML with recurrent abnormalities: 
AML with t(8;21)(q22;q22), inv(16)(p13.1q22) or t(16;16)(p13.1;q22) and APL with 
t(15;17)(q22;q12) are considered as acute leukaemia regardless of blast count in the blood or 
BM, but in contrast to the previous edition, for AML with t(9;11)(p22;q23) or other 11q23 
abnormalities, as well as for all other subgroups (except the rare instance of some cases of 
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erythroleukemia) blasts of 20% or more of white blood cells in peripheral blood (PB) or of all 
nucleated BM cells is required for the diagnosis of AML. 
The former FAB morphologic entities are now included as acute myeloid leukaemia not 
otherwise specified: 
AML with minimal differentiation (FAB M0) 
Medium-sized blasts with no signs of differentiation, with fine nuclear chromatin and 
agranular cytoplasm. Sometimes blasts are small, resembling lymphoblasts. The BM is 
usually hypercellular and survival is poor. 
AML without maturation (FAB M1) 
In the BM we usually find above 90% myeloblasts from nonerytroid cells with few signs of 
differentiation. Blast may have azurophilic granules and/or Auer rods, but most are 
agranular blasts. Sometimes blasts look like lymphoblasts and BM is typically hypercellular. 
The literature cites cases of AML - M1 with mirror cells (although they are most commonly 
found in acute lymphoblastic leukaemia) and even with Auer rods (Casasnovas et al., 2003). 
AML with maturation (FAB M2) 
This category represents 30-45% of AML. It is also the most frequent AML in children. We 
find 20% or more myeloblasts in the blood or BM and 10% or more neutrophils in various 
stages of maturation (promyelocytes, myelocytes and metamyelocytes). Monocytes 
represent less than 20% of BM cells. Myeloblasts can be with or without azurophilic 
granules and Auer rods. Abnormal nuclear segmentation of neutrophils and increased 
number of eosinophilic precursors are frequent. The BM is usually hypercellular. In some 
cases the immature cells have abundant cytoplasm and basophilia, with a variable number 
of granules, sometimes indistinguishably, sometimes coalescent, making difficult the 
difference between M1 and M2. 
Acute promyelocytic leukaemia (FAB M3) 
In the classic form the predominant cells are abnormal promyelocytes with many primary 
granules. Auer rods are frequent and often occur in bundles. In the mycrogranular version 
(M3v), leukaemic cells have monocytic aspect with cleaved nuclei and abundant cytoplasm 
with indistinguishable granules. 
Acute myelomonocytic leukaemia (FAB M4) 
This category accounts for between 15-25% of AML. Some patients have a history of chronic 
myelomonocytic leukaemia. It is characterized by the proliferation of neutrophilic and 
monocytic precursors, 20% or more myeloblasts, monoblasts and promonocytes being 
needed in the BM nucleated cells to distinguish between chronic myelomonocytic leukaemia 
and AML, and 5 x 109/L or more blood monocytes. 
Monoblasts are large size, with round nuclei, abundant cytoplasm and prominent nucleoli, 
and sometimes have fine azurophilic granules. There is the eosinophilic variant (M4Eo), in 
which eosinophils are increased in number (>5%) and this variant is associated with 
chromosome 16 abnormalities. 
Monoblastic acute leukaemia (FAB M5a) or acute monocytic leukaemia (FAB M5b) 
This is characterized by a percentage exceeding 80% of leukaemia cells of monocytic type: 
monoblasts, promonocytes and monocytes. The two differ in the relative proportions of 
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monoblasts and promonocytes. If most cells are monoblasts, it is M5a type (usually over 
80%), and if most cells are promonocytes, it is M5b type. 
Monoblastic acute leukaemia is characterized by large basophilic monoblasts, with 
abundant cytoplasm, with formation of pseudopods, round nuclei with one or more 
prominent nucleoli. Rarely Auer rods are observed. BM is hypercellular with an increased 
number of monoblasts. 
Monocytic acute leukaemia is characterized by the presence of promonocytes with irregular 
nuclei, with moderate basophilic cytoplasm and azurophilic granules. The erytrofagocitosis 
phenomenon can be seen. 
From a clinical point of view, M4 and M5 subtypes are accompanied with signs of 
medullary and extramedullary involvement: fever, fatigue, haemorrhage, gingival 
hyperplasia, hepato-splenomegaly, lymphadenopathy and involvement of the nervous 
system. Because the involvement of the central nervous system is frequent, the examination 
of cerebrospinal fluid is recommended, even if no clinical signs of involvement are present.  
Acute erythroid leukaemia (FAB M6)  
This includes erythroleukemia (M6a) and very rarely pure erythroblast leukaemia (M6b). 
The two types are characterized by the presence of a predominant erythroid population and 
in the case of M6a by the presence of an important myeloid component. M6 may be present 
de novo or evolve from a myelodysplastic syndrome. Occasionally, some cases of chronic 
myeloid leukaemia may develop into M6. Pancytopenia is a common feature. 
Over 50% of nucleated cells of the MO are abnormal erythroblast. Displastic changes in 
erythroblasts may be important: giant forms, multinucleated, cytoplasmic vacuolation and 
megaloblastoid change. 
Erythroleukemia (M6a) is characterized by 50% or more erythroid precursors from 
nucleated cells in the BM, 20% or more myeloblasts from non erythroid population in the 
BM, displastic erythroid precursors, with megaloblastoid nuclei and multinucleated 
erythroid cells. Dysplasia is also seen on the megakaryocytic line. Myeloblasts are of 
medium size, occasionally with Auer rods. Ringed sideroblasts can be present and the BM is 
usually hypercellular. This morphologic type represents the majority of acute erythroid 
leukaemias. Pure erythroblast leukaemia (M6b) is characterized by medium and large sized 
erythroblast with round nuclei, fine chromatin, one or more nucleoli, intense basophilic 
cytoplasm and occasionally coalescent vacuoles. 
Acute megakaryoblastic leukaemia (FAB M7) 
This represents 3-5% of AML, blast cells appertaining to the megakaryocytic line. It is 
characterized by cytopenia, displastic changes of neutrophils and platelets. 
Megakarioblasts are of medium to large size, with incised or round nuclei and with one or 
more nucleoli. Cytoplasm is basophilic, agranular with pseudopods. In some cases 
lymphoblast-like morphology (increased nuclear/cytoplasmic ratio) has been reported. We 
can frequently see in blood micromegakaryocytes circulating, fragments of megakaryocytes, 
large and displastic platelets and hypogranulated neutrophils. BM is often fibrous and BM 
puncture may be white (blinded). It presents with two peaks according to age: in children 1-
3 years old related with Down syndrome and in adults. According to 2008 WHO 
classification, myelodysplastic syndrome and AML related to Down syndrome are 
biologically identical and considered as myeloid leukaemia associated with Down 
syndrome.  
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Acute basophilic leukaemia 
This is a form of AML with primary differentiation to basophils. It is a rare, representing 1% 
of AML. It is accompanied by secondary signs of hyperhistaminemia, circulating blasts, 
organomegalia and BM failure. Morphologically it is characterized by medium-sized blasts 
with high nuclear/cytoplasmic ratio, round, oval, bilobate nucleus with one or more 
nucleoli, moderate basophilic cytoplasm containing a variable number of basophilic 
granules, red cell dysplasia and hypercellular BM. 
Acute panmyelosis with myelofibrosis  
This condition can occur at any age, de novo or after treatment with alkylating agents 
and/or radiation. There is an acute proliferation associated with fibrosis of BM. It is 
characterized by pancytopenia, marked anisocytosis, displastic change of myeloid line, 
hypercellular BM on the osteomedulary biopsy, varying degrees of hyperplasia of erythroid 
granulocytic, megakaryocytic precursors in BM, increased number of megakaryocytes with 
displastic changes and a marked increase in the number of reticulin fibres in BM. 
There are even some overlapping features with M7 subtype, the distinction is that in M7 the 
predominant population of blasts is of megakaryocytic origin and in acute panmyelosis with 
myelofibrosis it is of non-megakaryocytic origin. The prognosis is unfavourable.  
3.3.1 Particular morphological forms of acute myeloid leukaemia 
Acute myeloid leukaemia with cup-like morphology 
Various authors have attempted to characterize the morphology of AML with this special 
morphological appearance, raising questions as to whether this is a new disease entity or an 
artificial phenomenon (Barbaric et al., 2007; Benderra et al., 2005). Investigating the ’cup-
like’ morphology of 266 randomly selected patients with AML and association with 
haematological, immunological and prognostic parameters, it was found that this 
morphology was present in 21% of cases, was associated with the female sex, increased 
numbers of leukocytes and blast, normal karyotype, low expression of CD34 and HLA-DR. 
With regard to FLT3 mutations, NPM1 were found in 84.9% of cases, compared to 58.1% in 
cases without this morphology. Response to treatment and survival were not influenced in 
this study. Electronic microscopy showed that the cups contain lots of organelles. This 
particular form does not appear as a distinct category in any classification. It is sometimes 
difficult to do the differential diagnosis with acute promyelocytic leukaemia, the 
mycrogranular variant, in which neoplastic cells with prominent, bilobed nuclei can 
partially resemble blasts with cup-like nuclei. Immunophenotyping cannot identify the 
difference because both acute myeloid leukaemia with cup-like morphology and acute 
promyelocytic leukaemia are CD34- and HLA-DR-, with strong myeloperoxidase reaction. 
3.4 Biochemistry 
No specific biochemical pattern characterizes AML. Usually high activity of serum lactate 
dehydrogenase (LDH) is present. LDH is a biochemical marker reflecting tumour load and 
anaerobic glycolysis. When tissues are shifted from aerobic to the anaerobic glycolysis, LDH 
activity increases to accelerate the conversion of pyruvate to lactate, with the release of 
energy. At the molecular level, hypoxia induces expression of vascular-endothelial growth 
factor (VEGF) and fibroblasts growth factor (bFGF), and thus angiogenesis. Enhancing 
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angiogenesis is a phenomenon which was observed in AML. Studies have shown that the 
activity of serum LDH and not the concentrations of two growth factors (VEGF, bFGF) may 
be used as a parameter predictor for BM angiogenesis in AML (Teng et al., 2006). Another 
value of this marker is the prediction of tumour lysis syndrome (TLS), which usually occurs 
in patients with hyperleukocytosis. Despite the prophylactic use of allopurinol, morbidity 
and mortality related to tumour lysis syndrome (TLS) still occurs in some patients with 
AML. The criteria for tumour lysis syndrome are serum creatinine level over 1.4 mg/dL 
(normal range 0.5 to 1.4 mg/dL) and an increase of at least one of the following parameters: 
potassium > 5 mEq/L (normal range 3.7 to 5.0 mEq/L.), uric acid > 7.5 mg/dL (normal 
range 3.0 to 7.0 mg/dL), phosphate > 5 mg/dL (normal range 2.4 to 4.1 mg/dL) and calcium 
< 8 mg/dL (normal range 8.4 to 10.2 mg/dL). TLS can be a life-threatening complication in 
patients during induction therapy in AML. Characteristic laboratory changes may occur 
spontaneously before initiation of induction therapy due to catabolism and to increased 
turnover of leukaemic cells, but is most commonly induced by intensive chemotherapy. Yet 
few studies have focused upon TLS in AML, so the incidence and development of TLS in 
these patients are not well defined. A study that included 772 patients with AML treated 
with allopurinol and intense hydration showed that 17% of patients developed TLS. 
Multivariate analysis showed that pretreatment levels of LDH above the normal range, 
creatinine over 1.4 mg/dl, uric acid over 7.5 mg/dl and WBC count 25x109/L, were 
independent prognostic factors for TLS (Montesinos et al., 2008). In children with AML, life-
threatening pulmonary complications were cited in combination with TLS and mimic 
systemic inflammatory response syndrome (SIRS). Severe SRSI is more common in 
association with monocytic and myelomonocytic AML (M4, M4Eo, M5), especially in M4Eo.  
A mild or moderate increase of uric acid plasma level is frequent, especially in monocytic 
and myelo-monocytic AML. 
Changes of ions concentrations (sodium, potassium, calcium, hydrogen) are mild or 
moderate and infrequent. Hypokalemia is the most frequent finding at presentation, related 
to renal tubular dysfunction, and artifactual increase of potassium is associated in vitro in 
patients with hyperleukocytosis. Hypocalcaemia can appear as a result of multiple 
mechanisms, as direct skeletal invasion by malignant cells, ectopic parathyroid hormone 
(PTH) production or bone-resorbing cytokines. Hypophosphataemia as a result of 
leukaemic cell up-take, also can occur. Hyponatremia and lactic acidosis as presenting 
features of AML are rare. Hyponatremia is proposed to be due to inappropriate production 
of antidiuretic hormone by the leukaemic cells. There has been no well defined cause for 
lactic acidosis due to leukaemia per se, but probable explanations are due to anaerobic 
glycolysis by leukaemic cells and due to increased blast count with its attendant leukostasis 
(Udayakumar et al., 2006). 
Various abnormalities of coagulation are met in AML: decrease in α2 antiplasmin, 
antithrombin III and fibrinogen. Especially in promyelocytic acute leukaemia, there is a high 
risk for disseminated intravascular coagulation, because of procoagulants released from the 
cytoplasmic granules.  
3.5 Cytochemical stains 
Cytochemical stains with full analysis of blood and careful morphological examination of 
peripheral smear and BM help to classify most cases of AML. Research into signs of 
dysplasia is important work and it is hard to quantify cell dysplasia when the line is poorly 
represented (Braham-Jmili et al., 2006). 
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Cytochemical stains that characterize each morphological subtype are the following: 
M0 (AML with minimal differentiation) 
 Myeloperoxidase staining is negative (MPO) 
 Sudan Black staining is negative (SBB) 
 Naphthol chloroacetate esterase staining is negative (<3% positive blasts) 
 Alpha naphthyl acetate and butyrate esterase staining are negative 
 Periodic acid Schiff (PAS) staining is negative 
 This subtype can only be diagnosed using flow cytometry 
M1 (AML without maturation) 
 3% or more of the blasts positive for MPO and SSB 
 PAS is usually negative 
M2 (AML with maturation granulocyte) 
 A large number of blasts are MPO positive  
 PAS is usually negative 
M3 (promyelocytic) or acute promyelocytic leukaemia 
 Blasts are MPO and chloroacetate esterase positive 
 The hypogranular variant behave similarly regarding the cytochemical stains 
M4 (acute myelomonocytic leukaemia) 
 MPO positive in at least 3% of blasts 
 Monoblasts, promonocytes and monocytes are typically nonspecific esterase (NSE) 
positive 
Monoblastic M5 acute leukaemia (M5a) or acute leukaemia monocytic (M5b) 
 Typically NSE is strongly positive 
 MPO is negative, but the MPO may occasionally be positive in M5b 
 Lysozyme is positive 
M6 (erythroid acute leukaemia) 
 Red cell precursors are PAS positive  
 Blasts are MPO, SSB negative, but may be positive for NSE 
M7 (acute megakaryoblastic leukaemia) (23) 
 Stains are negative for MPO and SSB 
 Blasts can be PAS and NSE positive 
 This subtype can only be diagnosed using flow cytometry 
Acute basophilic leukaemia (26) 
 Blasts are acid phosphatase positive 
 MPO, SBB, NSE are negative 
Acute panmyelosis with myelofibrosis 
 In some cases blasts may be MPO positive 
Granulocytic sarcoma 
 Tumour cells may express myeloid associated molecules in the biopsies, such as MPO, 
NSE or lysozyme. 
3.6 Immunophenotyping 
Flow cytometry is a technique used for counting, examining and sorting microscopic 
particles suspended in fluid. It also allows multiparametric analysis of the physical and/or 
chemical characteristics of a single cell passing through an optical and/or electronic 
detection device. Immunophenotyping is an essential technique for the diagnosis, 
www.intechopen.com
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
142 
classification, staging and monitoring of leukaemia. In the last 10 years, expanding 
monoclonal antibodies (MoAb) and flurochromes allow differentiation of normal cell 
populations, of leukaemic cells, defining the state of maturation and recognition of aberrant 
phenotypes. 
Despite recommendations for standardization for multiparametric flow cytometry (Bene et 
al., 1995; Rothe & Schmitz, 1996; Stewart et al., 1997; Bain et al., 2002), the number, 
specificity and combination of reagents used for diagnosis and classification of acute 
leukaemia in different laboratories are varied. A study showed that using combinations of 
four MoAb from a minimum panel of 13 MoAb and CD45/sideward scatter gating strategy, 
achieved the correct classification in 97.2% of cases of acute leukaemia (155 patients), of 
which 79 were AML (Ratei et al., 2007).  
To monitor minimal residual disease (MRD), application of five-colour flow cytometry is 
more appropriate, enhancing sensitivity and precision of the method (Bacârea et al., 2007; 
Voskova et al., 2007). Another study also demonstrated that multiparametric flow cytometry 
in five colours is useful for the detection of leukaemia associated phenotypes in BM of 
patients with de novo AML and detection of MRD. Another study showed that the six-
colour cytometry allowed for the identification of leukaemia associated phenotypes that are 
not expressed in normal BM or postchimiotherapy and can be used successfully to monitor 
the MRD. The practical relevance of the multicolour approach is the ability to detect patients 
at high risk of relapse (Olaru et al., 2008). 
Immunophenotyping of acute leukaemia cells after density gradient separation is currently 
the gold standard, but the destruction of red blood cells after whole blood lysis and direct 
marking is a widespread and used procedure. In addition, data show that for both methods, 
the mean expression of antigens being tested was similar: CD4, CD7, CD11b, CD11c, CD13, 
CD14, CD15, CD33, CD34, CD65s, glycophorin A, HLA-DR (Schwonzen et al., 2007). For 
manual counting, blasts represent the percentage of total nucleated cells. For flow-
cytometric studies, the lysis step for removing erythrocytes, removes a variable number of 
red cell precursors. So, the obtained values determined by flow cytometry are a percentage 
of all analyzed cells or all nonerytroid cells. These differences also affect the use of flow 
cytometry to assess erythroleukemia, the erythroid/myeloid type, where the criteria require 
more than 50% red cell precursors of the total population of nucleated cells and above 20% 
myeloblasts from the nonerytroid population. Using cell separation with Ficol also leads to 
alteration of cell proportions and is strongly discouraged. On the other hand, blasts can be 
difficult to recognize on morphological examination, or are destroyed during preparation of 
blood or BM smears. So it is prudent to perform both immunophenotyping and 
morphological blast count (Craig & Foon, 2008). 
Usually, the expression of an antigen is considered positive if 20% or more blasts react with 
a specific antibody. Blast cells can be distinguished from myeloid precursors through the 
expression of immature markers CD34, CD117 and lack of maturity markers CD11b, CD15, 
CD16. Some blasts are negative for CD34 and CD117, and are difficult to distinguish from 
more mature cells. For example, it is difficult to distinguish mature monocytes from CD34 
negative monoblasts. Therefore, even if it is tempting, it is preferable not to make the 
selection of blasts according to CD34. CD117 antigen is expressed on the blasts, but also on 
mast cells. Mature myeloid cells when hypogranulated may fall below on the side scatter 
and may fall into the blasts window on CD45/side blasts scatter plot.  
www.intechopen.com
 
Diagnosis of Acute Myeloid Leukaemia 
 
143 
The advantages of flow cytometry are given by the possibility of quick analysis of several 
thousand cells, multiparametric analysis. It also allows the assessment of aberrant markers 
and mixed phenotypes and investigation of MRD. Disadvantages are the costs (an expensive 
device and antibodies), the panels that can change, problems of interpretation and the fact 
that the technique does not allow diagnosis of acute leukaemia, which is cytological. 
To standardize the work in specialized laboratories it is recommended an initial assessment 
of the line and then a secondary assessment. In the attempt to define the optimal number of 
markers to determine the immunophenotype in acute leukaemia with a sensitivity of 95%, 
some recommended markers for AML are: myeloperoxidase (MPO), CD33, CD13, CD14, 
CD15, CD117, CD34 (Lee et al., 2006). Other authors recommend wider panels with specific 
antibodies: CD13, CD14, CD15, CD33, CD64, CD117, CD36, MPO and antigens associated 
with haematopoietic cell maturation (CD34, CD38, TDT) and myeloid antigens (CD16, 
CD66). In addition, it is recommended to use other auxiliary markers in determining non-
specific antigens: CD7, CD19 and CD56 are very useful to monitor residual disease 
(Woźniak & Kopeć-Szlęzak, 2008). 
AML is regarded as a stem cell disease. In AML CD34 + leukaemic stem cells are recognized 
as CD38-. This CD34 + CD38- population survives chemotherapy and is most likely the 
cause of residual disease (MRD - with poor prognosis), which will then lead to relapse. 
Thus, by showing CD34 + CD38- malignant cells after chemotherapy, detection of MRD at 
stem cell level is possible (van Rhenen et al., 2007). 
Based on antigen positivity we can establish different immunological profiles: 
 Myeloblastic – CD13, CD33, CD117, CD15, HLA-DR usually positive 
 Myelomonocytic – CD11, CD13, CD33, CD14, HLA-DR usually positive 
 Erythroblastic – Glycophorin, spectrin, carbonic anhidrase I, HLA-DR usually positive 
 Promyelocytic – CD11, CD13, CD33, CD15 usually positive 
 Monocytic – CD11, CD13, CD33, CD14, HLA-DR usually positive 
 Megakaryoblastic – CD34, CD41, CD42, CD61, von Willebrand factor  
For practical reasons it is necessary that FAB classification and immunological profile 
correspond. 
M0 (AML with minimal differentiation) 
 CD 34 and HLA-DR usually positive, but CD38 is negative in most cases 
 Myeloid associated antigens often positive – CD13, CD33, CD117 
 About half of the cases express TdT and/or CD7 
 Monocytic markers are usually negative 
 Occasionally the blasts may aberrantly express CD10, CD19, CD2, CD56 
 Lack of lymphoid antigen expression: cyCD3 for T line, cyCD79 and cyCD22 for B line 
M1 (AML without maturation)  
 Myeloid associated antigens often positive – CD13, CD33 and CD117 
 CD34, HLA-DR. cyMPO are often positive 
M2 (AML with maturation granulocyte) 
 Myeloid associated antigens often positive – CD13, CD33 and CD117 
 CD34, HLA-DR, cyMPO are often positive 
 Occasionally the blasts may aberrantly express CD56, CD19 
 Monocytic markers are usually negative 
M3 (promyelocytic) or acute promyelocytic leukaemia 
 Leukaemic promyelocytes express strongly for MPO and SSB, and also for CD9, CD13, 
CD33 
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 CD34, HLA-DR are negative 
 Sometimes it is difficult to make a differential diagnosis between acute promyelocytic 
leukaemia, the hypogranular variant and acute myeloid leukaemia with cup-like 
morphology, because it is also characterized by the immunophenotype: CD34-, HLA-
DR-. Also, CD7 is usually negative and myeloid markers are often positive (CD13, 
CD33, CD117, myeloperoxidase). 
M4 (acute myelomonocytic leukaemia) 
 Myeloid antigens CD13, CD33 are often positive 
 Partial expression of CD34, MPO, CD11c, CD36, CD64, CD117, HLA-DR 
 Aberrant expression of CD2, CD7, CD56 
 CD14 may have partial expression or sometimes may be negative 
M5 (monoblastic acute leukaemia - M5a or acute monocytic leukaemia - M5b) 
 Monocytic markers are usually positive: CD11c, CD36, CD64, CD14 
 HLA-DR is positive 
 A small proportion of blasts express CD13, CD33, CD117, MPO (weak) 
 CD34 is usually negative 
 Aberrant expression of CD56 
 High levels of CD64 expression distinguish AML subtype - M5, but low expression of 
CD64 by itself does not distinguish between subtypes of AML M4 and M5. Some 
authors consider the association of CD68 and CD11b useful to differentiate M5a and 
M5b FAB subtypes, given that CD68 and CD11b expression are much higher in M5a 
than in M5b (Pagano et al., 2005). 
 When immuphenotyping cannot be done successfully (inadequate smears, white 
puncture) immunohistochemistry can identify the monocytoid component. The 
usefulness of CD163 (scavenger for haemoglobin molecule present on 
monocytes/macrophages) is well established (Garcia et al., 2008). 
M6 (erythroid acute leukaemia) 
 Erythroid precursors are usually positive: glycophorin, CD71 
 CD34, HLA-DR are negative 
 Myeloid, monocytic markers are negative 
M7 (acute megakaryoblastic leukaemia) 
 Platelet glycoproteins are positive both on the surface and intracytoplamatic – CD41, 
CD42, CD62 
 Sometimes megakaryoblasts may express CD36, CD7 
 HLA-DR is often negative 
Acute basophilic leukaemia  
 Some myeloid markers may be positive – CD13, CD33 
 CD34, HLA-DR are usually positive  
Acute panmyelosis with myelofibrosis  
 CD34 and myeloid antigens CD13, CD33, CD117, MPO are often positive 
 A small proportion of blasts express platelets associated antigens 
Granulocytic sarcoma 
 Sarcomas are a mixture of immature and mature myeloid cells. The marker’s presence 
is based on the balance between the two. 
Phenotype in myeloid leukaemia associated with Down syndrome 
 Usually Down syndrome is associated with megakaryoblastic acute leukaemia, being 
CD41, CD42, CD62 positive. 
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Different studies have tried to correlate immunophenotype with cytogenetic profile and 
clinical manifestations, showing that karyotype abnormalities and clinical manifestations are 
closely related to abnormal antigen expression in AML (Plesa et al., 2008; Thalhammer-
Scherrer et al., 2002; Zheng et al., 2008): 
 Co-expression of CD19 was found in subtypes M0, M1 and M2. 
 The expression of CD14 is associated with subtypes M4, M4Eo, M5b, accompanied by 
poor outcome, low complete remission rate and shorter survival. 
 Expression of CD7 was found in subtypes M0, M1, M2, M4 and most frequently in M5a. 
 Expressions of CD22, CD56, TDT were correlated with the presence of abnormal 
karyotype. 
 t(8;21) was present in M2 and strongly associated with expression 
CD15/CD19/CD34/CD56. 
 In the M3, although lymphoid markers were detected in a considerable number of 
cases, they were not highlighted in any patient with t(15;17).  
 In M4, CD2 and CD34 expression was associated with abnormal karyotype. CD2 
expression was higher in the M4Eo version, but had no correlation with inv(16). Other 
studies indicate the presence of CD2 in M4Eo and M3variant. 
 In M5 there was a higher expression of CD14 and CD56. 
 The expressions of CD4, CD7, CD14, CD56, TDT were correlated with clinical features: 
increased numbers of leukocytes, platelets and patient age. 
 The few studies investigating AML-M7 confirm the high heterogeneity of this subtype. 
Cytogenetic abnormalities in adults are frequently those of secondary leukaemia and 
few of them have a history and morphology with dishematopoesis. In children, besides 
the famous Down syndrome (DS) associated M7, t(1;21) is characterized by young age 
of onset, female sex, tumour presentation and low percentage of blasts in BM, 
sometimes without megakaryoblastic marrow involvement, but always with 
dismegakaryopoesis associated with micromegakaryocytes. It appears that these 
children generally respond well to intensive chemotherapy (Duchayne et al., 2003). 
3.6.1 Flow cytometry and minimal residual disease (BMR) 
It is known that flow cytometry can be used not only for diagnosis of AML, but also to 
monitor the BMR. Two highly sensitive methods, multiparametric flow cytometry and real-
time quantitative PCR (RQ-PCR), are widely used to monitor the BMR and disease 
management. Multiparametric flow cytometry is particularly useful for investigating the 
early clearance of blasts, and blast count after consolidation therapy. Later, BMR levels 
quantified by RQ-PCR in cases of AML with fusion gene had the highest prognostic power, 
the sensitivity of RQ-PCR being between 10-4 - 10-7. Both methods are able to detect early 
disease relapse. Multiparametric flow cytometry may be used for most patients, however, to 
be successfully applied, two concepts have emerged which should be carefully weighed up: 
to include only those leukaemia associated phenotypes that are absent in normal BM, 
respectively do not consider cases with less aberrant immunophenotypes for MRD 
monitoring. In most cases the phenotype at diagnosis is the same at relapse. But, this may be 
true for only a part of the leukaemic cells and the intensity of expression and aberrantly 
expressed antigens may change (Kern et al., 2008): 
 Lymphoid antigen expression (e.g. CD33+/CD2+/CD34+, CD34+/CD13+/CD19+) 
 Antigenic overexpression  
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(e.g. HLA-DR++/CD33++/CD34++, CD64++/CD4++/CD45++) 
 Lack of antigens (e.g. HLA-DR-/CD33+/CD34+) 
 Asynchronous antigen expression  
(e.g. CD15+/CD33+/CD34+, CD65+/CD33+/CD34+) 
3.7 Secondary acute myeloid leukaemia 
Secondary AML is a poorly defined term that usually refers to the AML that develops after 
a history of myelodysplastic syndrome (MDS), myeloproliferative neoplasm or 
myelodysplastic/myeloproliferative neoplasm (MDS/MPN). The 2008 WHO classification 
defined the cases with a history of MDS or MDS/MPN and have evolved to AML, or cases 
that have a myelodysplasia-related cytogenetic abnormality, or at least 50% of cells in two or 
more myeloid lineages that are dysplastic as myelodysplasia-related changes. Some cases 
previously assigned to the subcategory of AML not otherwise specified as acute erythroid 
leukaemia or acute megakaryoblastic leukaemia may be reclassified as AML with 
myelodysplasia-related changes (Vardiman et al., 2009). Secondary AML may occur after 
chemotherapy with alkylating agents or topoisomerase II inhibitors, after radiation or 
exposure to environmental carcinogens. The 2008 WHO classification classifies cases after 
use of alkylating agents or topoisomerase II inhibitors as therapy-related myeloid 
neoplasms. The question is whether secondary AML itself is associated with poor prognosis 
or whether this is due to association with some morphological and biological characteristics. 
Dysplasia in de novo AML is related to unfavourable prognosis, but has no prognostic 
relevance under intensive therapy. Since there is no correlation between cytogenetic risk 
subgroups and dysplasia, cytogenetics continues to have proven impact in both de novo 
AML and secondary AML. Cytogenetic abnormalities spectrum in secondary AML is similar 
to de novo AML, but the frequency of unfavourable cytogenetic abnormalities associated 
with high risk and intermediate risk (complex karyotype, trisomy 8, monosomy 7 and 
others) is higher in secondary AML. Survival of patients with therapy-induced AML is 
shorter than those with de novo AML within the same cytogenetic risk group. Genetic and 
molecular differences that determine the phenotype and prognosis of secondary AML still 
require several additional studies (Larson, 2007). 
3.8 Acute leukaemias of ambiguous lineage 
According to WHO 2008, the classification encompasses the following entities: 
 Acute undifferentiated leukaemia 
 Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2); BCR-ABL1 
 Mixed phenotype acute leukaemia with t(v;11q23); MLL rearranged 
 Mixed phenotype acute leukaemia, B-myeloid, NOS 
 Mixed phenotype acute leukaemia, T-myeloid, NOS 
 Provisional entity: natural killer (NK) cell lymphoblastic leukaemia/lymphoma: 
This is a rare subtype of acute leukaemia, which is much debated. Although the nature of 
NK cells is questionable, is a variant of leukaemia with distinct morphological features and 
immunophenotype (blasts express CD56, CD2, CD7 and are negative for B or myeloid 
antigens). The cases previously classified as ‘blastic natural killer cell leukaemia/lymphoma’ 
are now ‘myeloid related blastic plasmacytoid dendritic neoplasm’ (Vardiman et al., 2009). 
The requirements for assigning more than one lineage to a single blast population in mixed 
phenotype acute leukaemia (MPAL) are presented in Table 2. 
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For myeloid 
lineage 
Myeloperoxidase (flow cytometry, immunohistochemistry or 
cytochemistry) or monocytic differentiation (at least two of the 
following: nonspecific esterase, CD11c, CD14, CD64, lysozyme) 
For T lineage Cytoplasmic CD3 (flow cytometry with antibodies to CD3 epsilon 
chain; immunohistochemistry using polyclonal anti-CD3 antibody 
may detect CD3 zeta chain which is not T cell–specific) or surface 
CD3 (rare in mixed phenotype acute leukaemia) 
For B lineage 
(multiple antigens 
required) 
Strong CD19 with at least one of the following strongly expressed: 
CD79a, cytoplasmic CD22, CD10 or weak CD19 with at least two of 
the following strongly expressed: CD79a, cytoplasmic CD22, CD10 
Table 2. The requirements for assigning more than one lineage to a single blast population in 
mixed phenotype acute leukaemia (MPAL). 
The former European Group of Immunological Markers for Leukaemia (EGIL) scoring 
system to evaluate biphenotypic acute leukaemia (BAL) had limitations because of over-
diagnosis of BAL, plus it ignored the cytogenetic data. Because of this, well defined genetic 
abnormalities could be classified as BAL. The new classification includes cytogenetics in the 
evaluation of MPAL. A lot of studies showed that when applying the 2008 WHO 
classification the number of MPAL decreased (BAL became ALL with aberrant myeloid 
markers or AML with aberrant lymphoid markers). The pitfall still remains the over-
diagnosis of MPAL, because of misinterpretation of immunological studies (e.g. 
immunophenotyping for MPO). Regarding MPO, it is preferable, if possible, to have both 
immunophenotyping and cytochemistry to consider it positive. Care must be taken, for 
example, not to consider as MPAL the patients with t(9;22) in blast crisis with former 
chronic myeloid leukaemia (CML). Cases of BCR-ABL1 positive and MLL positive acute 
leukaemias may meet the criteria for MPAL (Vardiman et al., 2009). 
3.9 Cytogenetics 
Compared with the 2001 WHO classification, the number of recognized recurrent genetic 
abnormalities has grown. The current 2008 WHO classification recognizes the importance of 
recurrent genetic abnormalities, which are crucial for correct diagnosis and treatment of AML: 
 AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
 APL with t(15;17)(q22;q12); PML-RARA 
 AML with t(9;11)(p22;q23); MLLT3-MLL 
 AML with t(6;9)(p23;q34); DEK-NUP214 
 AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
 AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
 Provisional entity: AML with mutated NPM1 
 Provisional entity: AML with mutated CEBPA  
The detection of recurrent genetic abnormalities requires cytogenetics - karyotyping, 
fluorescence in situ hybridization (FISH) and molecular analysis - reverse transcriptase 
polymerase chain reaction (RT-PCR). 
The new classification is helpful for clinicians because data can provide more prognostic 
significance. Cytogenetics currently provides the most important prognostic information 
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both at diagnosis and at relapse. Given the progress made in recent years on understanding 
disease pathogenesis, given the profile of the genes, new therapeutic targets will develop, 
with the hope that this new agents potentially will improve the disease (Avivi & Rowe, 
2005). Cytogenetic abnormalities have a frequency of 85% in de novo AML and 95-100% in 
secondary AML, consistent abnormalities being classified as specific (constant) and 
nonspecific (random). They can be balanced (translocations or chromosomal 
rearrangements) and unbalanced (chromosome loss or acquisitions). The specific, balanced 
abnormalities are present with a higher frequency in a given morphological FAB subtype. 
There are evidences for more than 80 balanced chromosomal rearrangements: [t(8:21) in 
AML2, inv16 in AML4 eosinophilic variant, t(9:11) in AML5, t(11:19) in AML4]. Constant 
unbalanced abnormalities (-7, -5) appear in all morphological subtypes. Some of these 
abnormalities are good prognostic factors [t(8; 21) (Q22, Q22 - fusion AML1-ETO), t(15; 17) 
(Q22, Q12 ~ 21 - fusion PML-RARA), inv (16 )(p13q22) / t (16; 16) (p13; Q22 - CBFB-MYH11 
fusion)], and others poor prognostic factors (5 -, 7 -, 5q-, 7q-, trisomy 8, trisomy 11, t (6, 9) or 
combinations). AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 is a common leukaemia 
usually associated with AML with maturation morphology and sometimes with 
myelomonocytic morphology. Auer rods are frequent. Eosinophilia and basophilia are 
common features. Displastic changes and association with myeloid sarcomas may also been 
seen. AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 may be associated 
with other cytogenetic abnormalities like trisomy 21, 8, loss or deletion of Y chromosome. It 
is associated with BM eosinophilia and lymphadenopathy. APL is one variant of AML 
associated with t(15;17). It is the retinoic acid receptor α gene (RARα) that is affected. In 
acute promyelocytic leukaemia, the variant RARA translocations with other partner genes 
should be considered separately, because of different features and different responses to 
treatment. Generating chimerical fusion proteins from chromosomal translocations results 
in blocking cell differentiation and contributes to the biological characteristics of different 
subtypes of leukaemia, representing the primary event in the pathogenesis of AML. In 
recent years it has become clear that other mutations have a role in pathogenesis: 
 Mutations of genes encoding transcription factors involved in haematopoiesis (often in 
AML1-M0, CEPBA - common in M1, M2) 
 Mutations of genes that encode components of the signal translation pathways, 
mutations in the tyrosine kinase receptor (FLT3 gene - confers proliferative advantage) 
 Mutations in genes that encode nucleophosmin (NPM1 - nucleocytoplasmatic protein 
involved in regulating gene expression - 35% of cases of AML) (Dohner et al., 2005; 
Falini et al., 2005; Schnittger et al., 2005) 
Extensive studies have proposed a system of risk stratification based on cytogenetics in 
AML patients who fall into three risk categories: favourable, intermediate and poor. The 
information obtained from diagnosis is used to further stratify therapy. For patients with 
abnormal karyotype before treatment, cytogenetic analysis has been recommended to 
document complete remission (CR), based on data showing that the persistence of even a 
single metaphase with an abnormality present at diagnosis leads to significantly higher 
incidence of relapse (Cheson et al., 2003). Because multilineage dysplasia is not associated 
with independent prognostic significance when cytogenetics is taken into account, the 2008 
WHO classification named this group ‘AML with myelodysplasia-related changes’. The 
cytogenetic abnormalities sufficient for diagnosis of AML with myelodysplasia-related 
changes when 20% or more PB or BM blasts are present are shown in Table 3: 
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Complex karyotype  
Unbalanced abnormalities  Balanced abnormalities  
-7 or del(7q)  
-5 or  
i(17q) or t(17p)  
-13 or del(13q)  
del (11q) 
del (12p) or t(12p) 
del(9q) 
Idic(X)(q13) 
t(11;16)(q23;p13.3) 
t(3;21)(q26.2;q22.1) 
t(1;3)(p36.3;q21.1) 
t(2;11)(p21;q23) 
t(5;12)(q33;p12) 
t(5;7)(q33;q11.2) 
t(5;17)(q33;p13) 
t(5;10)(q33;q21) 
t(3;5)(q25;q34) 
Table 3. Cytogenetic abnormalities sufficient for diagnosis of AML with myelodysplasia-
related changes 
Even if we have patients with therapy-related AML or with myelodysplasia-related 
changes, it is better to classify them according to their cytogenetic abnormalities. Still, 
because the outcome in patients with therapy related AML is worse than in those with de 
novo AML, it is important to correctly classify the therapy related AML, because it could 
bring important pathogenetic information and as it well known that not all patients taking 
such treatment develop AML (Vardiman at al., 2009). 
As is known, patients with AML with normal karyotype are the largest group and are 
classified as intermediate risk. They should be analyzed for FLT3, NPM1 and CEBPA 
mutations, and, if present, the abnormality should be noted in the diagnosis. FLT3 gene 
encodes a member of the class III receptor tyrosine - kinase, which is expressed on the 
surface of haematopoietic progenitors from BM, with a role in the survival and 
differentiation of pluripotent stem cells. FLT3 - ITD encodes a protein that causes abnormal 
activation and stimulates autophosphorylation of the receptor, activating the pathway 
below. Results of studies show the FLT3-ITD as a strongly independent negative prognostic 
factor influencing remission duration and survival in the group with normal karyotype, 
located in the intermediate cytogenetic risk group. Mutation is found in 28-33% of cases. 
Additional mutations that occur in the signal transduction molecules (receptor tyrosine 
kinase - c-kit and FLT3, NRAS and KRAS) are required to generate the disease. FLT3 is 
overexpressed in most cases of AML and is mutated in approximately 35% of cases of AML. 
These mutations lead to activation of FLT3 with activation of anti–apoptotic pathways. In 
addition, it activates MAPK (mitogen activated protein kinase), AKT and Stat5 (signalling 
molecules) leading to activation of Pim-1 (proto-oncogene which encodes a cytoplasmic 
serine - threonine kinase) and overexpression of Bcl-XL (protein inhibiting cell death and 
inhibiting caspase activation, thereby inhibiting apoptosis). Simultaneous blockage of both 
caspase pathways predict poor response to chemotherapy and is prognostic for decreased 
overall patient survival (Schimmer et al., 2003).  
Nucleophosmin mutations have been reported in 46-62% of cases of AML with normal 
karyotype, as the most frequent gene alteration in this group of AML cytogenetics. NPM1 
mutations have been associated with pre-treatment characteristics such as female sex, higher 
percentage of blasts in MO, elevated levels of lactate dehydrogenase (LDH), increased 
number of leukocytes, platelets and low or absent expression of CD34 marker. 
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Approximately 40% of patients with NPM1 mutations also harbour FLT3-ITDs, which 
together with the tyrosine kinase domain mutations (FLT3-TKD), are twice as common in 
NPM1 positive patients as those with wild-type NPM1. CEBPA mutations occur with 
similar frequency in patients with and without NPM1 mutations. Many studies have shown 
that NPM1 mutation is associated with clinical outcome. Cytoplasmic localization of 
nucleophosmin is a favourable prognostic factor for achieving CR (Schnittger et al., 2005). 
CEBPA mutations (enhancer binding protein - the gene encodes a myeloid transcription 
factor and plays an important role in normal granulopoesis) were detected in 15-20% of 
cases of AML with normal karyotype. These cases, compared to wild-type mutation, have a 
higher percentage of blasts in peripheral blood and decreased numbers of platelets, but 
lymph and extramedullary involvement is much rarer and less likely to carry FLT3-ITD, 
FLT3-TKD and MLL-PTD. Regarding MLL, although the t(9;11)(p22;q23) is clearly named in 
the classification, it is recommended that variant MLL translocation also be specified in the 
diagnosis, for example, AML with t(11;19)(q23;p13.3); MLL-ENL. MLL-PTD should not be 
classified in this category (Gaidzik & Döhner, 2008; Marcucci et al., 2008; Mrózek et al., 2007; 
Vardiman et al., 2009). Cytogenetically normal AML with CEBPA mutations is associated 
with favourable prognosis. Some recent studies suggest that there is a heterogeneity among 
mutated CEBPA AML and just the cases with double, biallelic mutations have a favourable 
outcome (Barjesteh van Waalwijk van Doorn-Khosrovani et al., 2003; Fröhling et al., 2004; 
Preudhomme et al., 2002; Schlenk et al., 2008). The question of whether the presence of a 
FLT3-ITD has an impact on prognosis in patients with CEBPA mutations remains open 
(Renneville et al., 2009; Schlenk et al., 2008). 
Down related AML harbour the same molecular abnormality – GATA1 mutation and also 
other features (clinical, morphological and immunophenotypical) and this was the reason 
for their separation in the myeloid proliferations related with the Down syndrome category. 
4. Differential diagnosis 
Regarding the distinction between subtypes of AML, the most important and with 
consequences for treatment is that between APL and other AML subtypes. APL, especially the 
hypogranular variant, may look like AML with monocytic differentiation. Leukaemic 
promonocytes often have Auer rods and are MPO strongly positive. The immunophenotype is 
different, leukaemic promonocytes being negative for CD34, HLA-DR and monocytic markers. 
AML with multilineage dysplasia must be distinguished from refractory anaemia with 
blasts excess (RAEB). The presence of 20% blasts in peripheral blood or BM makes the 
difference. In order to have the diagnosis of AML with multilineage dysplasia, patients must 
have 20% or more blasts in the PB or BM and evolve from previously MDS or MDS/MPN, 
specific myelodysplasia-related cytogenetic abnormalities (see Table 3), or present dysplasia 
in 50% or more of the cells in two or more myeloid lineages. 
The differential diagnosis of acute megakaryoblastic leukaemia includes AML without 
differentiation, idiopathic myelofibrosis, acute panmyelosis with myelofibrosis and 
metastases of BM. The presence of Down syndrome, megakarioblasts in peripheral blood, 
the positivity of CD41, CD42 and CD61 pleads for the diagnosis of acute megakarioblastic 
leukaemia. In acute panmyelosis with myelofibrosis, the blasts are of non megakaryocytic 
origin. Care must be taken in patients with hypoplastic and oligoblastic leukaemia when 
examining specimens of BM, where the diagnosis is made on the presence of ≥ 20% blasts in 
the hypocellular marrow. 
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The difference between AML and ALL is easy to assess using immunophenotyping. 
Chronic myeloid leukaemia (CML) in myeloid blast crisis can mimic AML, but the presence 
of the Philadelphia chromosome, splenomegaly and myeloid cells at all levels of 
differentiation distinguish CML from AML. Acute basophilic leukaemia is another entity to 
consider, knowing the characteristic basophilia. Care must be provided for example not to 
consider as MPAL the patients with t(9;22) in blast crisis with former CML. The 2008 WHO 
classification shows that there is the atypical CML category, that is BCR-ABL1–negative, and 
it is not a variant of CML, BCR-ABL1–positive. On the other hand, cases of BCR-ABL1–
positive AML have been reported, but because it is difficult to distinguish it from CML in 
blastic crisis, the 2008 classification does not recognize it (Vardiman et al., 2009). 
Leukaemoid reactions and nonleukaemic pancytopenia can be differentiated from AML 
because the blasts are missing in blood or BM. Sometimes in infections, such as tuberculosis, 
the proportion of blasts in the marrow may increase, but it does not reach the proportion of 
blasts required for a diagnosis of AML.  
Pseudoleukaemia is a condition usually met after administration of granulocyte colony 
stimulating factor. Attentive observation of patients clarifies the problem, because in a short 
time the morphological appearance of BM will normalize. In the beginning it is manifested 
with severe leukopenia and usually normal thrombocytes. 
Agranulocytosis is an acute condition involving severe leukopenia most commonly 
neutropenia in the circulating blood. The concentration of granulocytes falls below 100 
cells/mm³ of blood. When infection and bleeding are present the diagnosis is more 
complicated. With examination of BM, a history of drug use helps in giving the correct 
diagnosis. 
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